Amgen: Allowing Dividend Growth Investors To Capitalize On The Biotech Sell-Off

Home › Amgen: Allowing Dividend Growth Investors To Capitalize On The Biotech Sell-Off

In my opinion, Amgen is the only viable option for a conservative income investor looking for large-cap exposure to biotech.

18.05	Eastern North Pacific Tropical Weather Outlook
18.05	Atlantic Tropical Weather Outlook
17.05	House Republicans release farm bill draft
17.05	House Republicans release farm bill draft
17.05	Union forming stalled in US Mercedes-Benz
17.05	Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05	Register For Sustainable Cosmetics Summit
17.05	Fewer crackers in Ritz boxes but price remains same
More »

je.st